{"name": "Alkermes",
 "permalink": "alkermes",
 "crunchbase_url": "http://www.crunchbase.com/company/alkermes",
 "homepage_url": "http://www.alkermes.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "busdev@alkermes.com",
 "phone_number": "781.609.6000 ",
 "description": "Biotechnology company",
 "created_at": "Tue May 10 02:34:02 UTC 2011",
 "updated_at": "Sat Mar 09 11:58:51 UTC 2013",
 "overview": "\u003Cp\u003EAlkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone, as a once-monthly injectable medication for the treatment of alcohol dependence. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       46],
      "assets/images/resized/0013/3906/133906v1-max-150x150.png"],
     [[198,
       62],
      "assets/images/resized/0013/3906/133906v1-max-250x250.png"],
     [[198,
       62],
      "assets/images/resized/0013/3906/133906v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman and CEO",
    "person":
     {"first_name": "Richard",
      "last_name": "F. Pops",
      "permalink": "richard-f-pops",
      "image":
       {"available_sizes":
         [[[141,
            150],
           "assets/images/resized/0024/1242/241242v1-max-150x150.png"],
          [[236,
            250],
           "assets/images/resized/0024/1242/241242v1-max-250x250.png"],
          [[265,
            280],
           "assets/images/resized/0024/1242/241242v1-max-450x450.png"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "VP of Regulatory Affairs",
    "person":
     {"first_name": "Cheryl",
      "last_name": "Larrivee-Elkins",
      "permalink": "cheryl-larrivee-elkins",
      "image":
       {"available_sizes":
         [[[100,
            150],
           "assets/images/resized/0025/1928/251928v1-max-150x150.jpg"],
          [[150,
            225],
           "assets/images/resized/0025/1928/251928v1-max-250x250.jpg"],
          [[150,
            225],
           "assets/images/resized/0025/1928/251928v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "President",
    "person":
     {"first_name": "Shane",
      "last_name": "Cooke",
      "permalink": "shane-cooke",
      "image":
       {"available_sizes":
         [[[141,
            150],
           "assets/images/resized/0024/1240/241240v1-max-150x150.png"],
          [[236,
            250],
           "assets/images/resized/0024/1240/241240v1-max-250x250.png"],
          [[265,
            280],
           "assets/images/resized/0024/1240/241240v1-max-450x450.png"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Research / Regulatory",
    "person":
     {"first_name": "Guy",
      "last_name": "Van Meter",
      "permalink": "guy-van-meter",
      "image":
       {"available_sizes":
         [[[124,
            124],
           "assets/images/resized/0027/1425/271425v1-max-150x150.jpg"],
          [[124,
            124],
           "assets/images/resized/0027/1425/271425v1-max-250x250.jpg"],
          [[124,
            124],
           "assets/images/resized/0027/1425/271425v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "852 Winter Street",
    "address2": "",
    "zip_code": "02451",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Alkermes buys Elan's delivery unit in $960M buyout deal",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 9,
    "source_url": "http://www.fiercebiotech.com/story/alkermes-buys-elans-delivery-unit-960m-buyout-deal/2011-05-09?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Alkermes buys Elan's delivery unit in $960M buyout deal",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Alkermes",
      "permalink": "alkermes"}},
   {"description": "acquiring the Elan Drug Technologies unit of Ireland\u00e2\u20ac\u2122s Elan Corp. plc in a cash and stock merger deal worth approximately $960 million that will see Alkermes Inc. relocate its headquarters officially to Dublin, Ireland, and become Alkermes plc",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2011/05/09/daily1-Alkermes-buying-Elan-drug-unit-changing-HQ-location-to-Dublin.html",
    "source_text": null,
    "source_description": "Alkermes buying Elan drug unit, changing HQ location to Dublin",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Alkermes",
      "permalink": "alkermes"}},
   {"description": "returned positive results from its Phase 1b study of ALKS 9070, its treatment for schizophrenia",
    "stoned_year": 2011,
    "stoned_month": 6,
    "stoned_day": 30,
    "source_url": "http://www.masshightech.com/stories/2011/06/27/daily41-Alkermes-schizophrenia-treatment-hits-on-positive-data.html",
    "source_text": null,
    "source_description": "Alkermes' schizophrenia treatment hits on positive data",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Alkermes",
      "permalink": "alkermes"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:ALKS"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        108],
       "assets/images/resized/0024/1243/241243v1-max-150x150.jpg"],
      [[250,
        180],
       "assets/images/resized/0024/1243/241243v1-max-250x250.jpg"],
      [[450,
        325],
       "assets/images/resized/0024/1243/241243v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}